US 11,884,697 B2
Oxysterols and methods of use thereof
Albert Jean Robichaud, Boston, MA (US); Francesco G. Salituro, Marlborough, MA (US); Gabriel Martinez Botella, Wayland, MA (US); Boyd L. Harrison, Princeton Junction, NJ (US); and John Gregory Reid, Wellington, FL (US)
Assigned to Sage Therapeutics, Inc., Cambridge, MA (US)
Filed by Sage Therapeutics, Inc., Cambridge, MA (US)
Filed on Apr. 28, 2021, as Appl. No. 17/242,860.
Application 17/242,860 is a continuation of application No. 16/089,896, abandoned, previously published as PCT/US2017/025535, filed on Mar. 31, 2017.
Claims priority of provisional application 62/317,002, filed on Apr. 1, 2016.
Prior Publication US 2021/0261598 A1, Aug. 26, 2021
Int. Cl. A61K 31/57 (2006.01); C07J 9/00 (2006.01); C07J 17/00 (2006.01); C07J 43/00 (2006.01)
CPC C07J 9/00 (2013.01) [A61K 31/57 (2013.01); C07J 17/00 (2013.01); C07J 43/003 (2013.01)] 27 Claims
 
1. A compound of Formula (I-B):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
R1 is hydrogen or substituted or unsubstituted C1-6 alkyl;
R5 is absent or hydrogen;
Z is —C(RA)2—, —NRB—, —O—, or —S—;
X is halogen, substituted or unsubstituted C1-6 alkyl, or —ORC;
RA is hydrogen, halogen, or substituted or unsubstituted C1-6 alkyl;
RB is hydrogen, substituted or unsubstituted C1-6 alkyl, —C(O)RC, —C(O)ORC, —C(O)N(RD)2, or —S(O)2RC;
RC is hydrogen or substituted or unsubstituted C1-6 alkyl;
each RD is independently hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
m is an integer selected from 1, 2, and 3;
n is an integer selected from 1, 2, and 3;
p is an integer selected from 0, 1, 2, 3, 4, and 5; and
custom character represents a single or double bond, wherein when one custom character is a double bond, then the other custom character is a single bond and R5 is absent.